{
    "name": "avalglucosidase alfa",
    "comment": "Rx",
    "other_names": [
        "Nexviazyme",
        "avalglucosidase alfa-ngpt"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/nexviazyme-avalglucosidase-alfa-4000181",
    "pregnancy": {
        "common": [
            "Data are insufficient to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; however, available data from postmarketing reports and published case reports on alglucosidase alfa (another hydrolytic lysosomal glycogen-specific enzyme replacement therapy) use in pregnant females have not identified drug-associated risk of adverse pregnancy outcomes",
            "Pregnant females exposed, or their healthcare providers, should report exposure by calling 1-800-745-4447, extension 15500"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Untreated Pompe disease may result in worsening respiratory and musculoskeletal symptoms in pregnant females "
                ]
            },
            {
                "type": "Animal studies",
                "description": [
                    "Embryofetal toxicity studies performed in pregnant mice resulted in maternal toxicity related to immunologic response (including anaphylactoid response) and embryofetal loss at 17 times the human steady-state AUC at the recommended biweekly dose of 20 mg/kg for patients weighing ≥30 kg or 10 times the human steady-state AUC at the recommended biweekly dose of 40 mg/kg for lat-onset Pompe disease patients weighing <30 kg",
                    "Avalglucosidase alfa-ngpt did not cross the placenta in mice; therefore, the adverse effects were likely related to the immunologic response in the mothers",
                    "Embryofetal toxicity studies performed in pregnant rabbits showed no adverse effects on fetuses at exposure up to 91 times the human steady-state AUC at recommended biweekly dosage of 20 mg/kg for patients weighing ≥30 kg or 50 times human steady-state AUC at the recommended biweekly dose of 40 mg/kg for weight <30 kg"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are unavailable regarding presence in human or animal milk, effects on breastfed infants, or effects on milk production",
            "Available published literature suggests the presence of alglucosidase alfa (another hydrolytic lysosomal glycogen-specific enzyme replacement therapy) in human milk",
            "Lactating females exposed, or their healthcare providers, should report exposure by calling 1-800-745-4447, extension 15500"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Hypersensitivity",
                    "description": [
                        "Life-threatening hypersensitivity reactions, including anaphylaxis, reported",
                        "Assure appropriate medical support measures, including cardiopulmonary resuscitation equipment, are readily available during administration",
                        "Discontinue drug immediately if a severe hypersensitivity reaction (eg, anaphylaxis) occurs and implement appropriate medical treatment",
                        "Consider desensitization procedure for patients with severe hypersensitivity reaction"
                    ]
                },
                {
                    "type": "Infusion-associated reactions",
                    "description": [
                        "Severe infusion-associated reactions (IARs) reported",
                        "Consider immediate discontinuation if severe IARs occur and initiate appropriate medical treatment",
                        "Reassess benefits and risks of continuing infusion/therapy following severe IARs",
                        "Patients with an acute underlying illness at the time of infusion may be at greater risk for IARs",
                        "Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs"
                    ]
                },
                {
                    "type": "Cardiorespiratory failure",
                    "description": [
                        "Monitor vital signs more frequently during infusion in at risk patients as described below",
                        "High risk of serious exacerbation of their cardiac or respiratory status during infusion include patient who",
                        "Are susceptible to fluid volume overload",
                        "Have acute underlying respiratory illness",
                        "Have compromised cardiac or respiratory function for whom fluid restriction is indicated (fluid from infusion may exacerbate cardiac or respiratory status)"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Also see Black Box Warnings and Dosage Modifications",
                "Severe hypersensitivity reaction (eg, anaphylaxis) reported; if this occurs, discontinue immediately and administer appropriate medical treatment; may consider desensitization",
                "IARs reported; immediate discontinuation required if severe; milder reactions may be managed by slowing infusion rate; antihistamines, antipyretics, and/or corticosteroids may be administered before infusion to reduce risk; Some patients have been rechallenged using slower infusion rates at a dose lower than recommended dose; once a patient tolerates infusion, the dose may be increased to reach recommended approved dose ",
                "Risk of acute cardiorespiratory failure reported in patients susceptible to fluid overload and those with acute underlying respiratory illness or compromised cardiac/respiratory function; monitor vital signs more frequently ",
                "Patients and their caregivers should be encouraged to participate in the Pompe Registry and advised that their participation is voluntary and may involve long-term follow-up; for more information regarding the registry program, visit www.registrynxt.com or call 1-800-745-4447, extension 15500 "
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "ADA cross",
            "percent": "3"
        },
        {
            "name": "reactivity studies showed that antibodies to avalglucosidase alfa",
            "percent": "95"
        },
        {
            "name": "ngpt were cross",
            "percent": "28"
        },
        {
            "name": "reactive to alglucosidase alfa",
            "percent": "39"
        },
        {
            "name": "Treatment",
            "percent": "3"
        },
        {
            "name": "naïve ADA baseline",
            "percent": "95"
        },
        {
            "name": "ADA after treatment",
            "percent": "28"
        },
        {
            "name": "Neutralizing antibody",
            "percent": "39"
        },
        {
            "name": "NAb",
            "percent": "10-74"
        },
        {
            "name": "inhibition of enzyme activity",
            "percent": "17-55"
        },
        {
            "name": "NAb inhibition of enzyme cellular uptake",
            "percent": "18"
        },
        {
            "name": "ADA baseline",
            "percent": "10-21"
        },
        {
            "name": "ADA after treatment",
            "percent": "10-74"
        },
        {
            "name": "Neutralizing antibody",
            "percent": "17-55"
        },
        {
            "name": "NAb",
            "percent": "18"
        },
        {
            "name": "inhibition of enzyme activity",
            "percent": "10-21"
        },
        {
            "name": "NAb inhibition of enzyme cellular uptake",
            "percent": null
        },
        {
            "name": "Treatment",
            "percent": null
        },
        {
            "name": "experienced ADA baseline",
            "percent": null
        },
        {
            "name": "ADAs after treatment",
            "percent": null
        },
        {
            "name": "NAb inhibition of enzyme activity",
            "percent": null
        },
        {
            "name": "NAb inhibition of enzyme cellular uptake",
            "percent": null
        },
        {
            "name": "ADA baseline",
            "percent": null
        },
        {
            "name": "ADAs after treatment",
            "percent": null
        },
        {
            "name": "NAb inhibition of enzyme activity",
            "percent": null
        },
        {
            "name": "NAb inhibition of enzyme cellular uptake",
            "percent": null
        }
    ]
}